Early Minimally Invasive Image Guided Endoscopic Evacuation of Intracerebral Haemorrhage (EMINENT-ICH)
- Conditions
- Intracerebral Haemorrhage
- Interventions
- Procedure: Best medical treatment (BMT)Procedure: Early minimally invasive image guided endoscopic hematoma evacuation
- Registration Number
- NCT05681988
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Brief Summary
This is an open-labelled, single centre randomised controlled trial evaluating the efficacy of early minimally invasive image-guided hematoma evacuation in combination with the current best medical treatment compared to best medical treatment alone in improving functional outcome rates at 6 months after initial treatment in patients with spontaneous supratentorial intracerebral haemorrhage.
- Detailed Description
Spontaneous supratentorial intracerebral haemorrhage (SSICH) is the second most common form of stroke and accounts for approximately 2500 cases in Switzerland annually. The prognosis is very poor with nearly half of the patients dying within one year after haemorrhage. Treatment options for SSICH consist of either the current gold standard, best medical treatment (BMT), or surgical hematoma evacuation. Neither the best medical treatment nor the established surgical mainstay (conventional craniotomy) have shown relevant improvement of survival or functional outcome rates. A minimal invasive approach with early image-guided endoscopic surgery conducted within 24 hours after bleeding onset is therefore proposed. Endoscopic surgery was shown to be safe and effective, however large trials analyzing the benefits of endoscopic surgery are lacking. An earlier, more complete and more rapid hematoma evacuation could improve the functional outcome and mortality rates in affected patients. The primary objective of this two-armed, open-labelled, single centre randomised controlled trial is to show superiority of early minimally invasive image-guided hematoma evacuation additionally to BMT compared to BMT alone in improving functional outcome rates at 6 months in patients with SSICH. The study procedures include 6 visits in total, 4 of them during hospital stay, 2 of them as follow-up visits within the clinical routine. Each visit consists of assessing Glasgow Coma Scale (GCS), modified Rankin Scale (mRS) and National Institute of Health Stroke Scale (NIHSS), three visits include CT scans (before intervention, directly postoperative and during follow up) and blood sampling (before intervention, postoperative and during follow up). Three visits include assessing patient satisfaction and cognition, and two visits include patient quality of life assessments. This study was designed in collaboration with Patient and Public representatives.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
-
Spontaneous supratentorial intracerebral hemorrhage (SSICH), defined as the sudden occurrence of bleeding into the lobar parenchyma and/or into the basal ganglia and/or thalamus that may extend into the ventricles confirmed by imaging
-
SSICH volume ≥20 mL <100 mL
-
A focal neurological deficit consisting of either
- clinically relevant hemiparesis (≥4 motor points on the NIHSS for facial palsy, motoric upper and lower extremities combined)
- clinically relevant motor or sensory aphasia (≥2 points on the NIHSS)
- clinically relevant hemi-inattention (formerly neglect, 2 points on the NIHSS)
- decreased level of consciousness (Glasgow Coma Scale (GCS)≤13)
-
Presenting GCS 5 - 15 (in intubated patients GCS assessment will be performed after Rutledge et al. or if impossible, the last pre-intubation GCS will be used)
-
Endoscopic hematoma evacuation can be initiated within 24 hours after the patient was last seen well/symptom onset
-
Informed consent of patient or appropriate surrogate (for patients without competence)
- SSICH due to known or suspected structural abnormality in the brain (e.g. vascular malformation, aneurysm, arteriovenous malformation (AVM), brain tumor) and/or brain trauma and/or hemorrhagic conversion of an ischemic infarction
- Multiple simultaneous intracranial hemorrhages (ICH) (e.g. multifocal ICH, chronic subdural hematoma (cSDH), acute subdural hematoma (aSDH), SAH)
- Infratentorial hemorrhage or midbrain extension/involvement of the hemorrhage
- Coagulation disorder (including anticoagulation) with an international normalized ratio (INR) of >1.5 which cannot be pharmacologically reverted until the planned time of evacuation
- Pregnancy
- Relevant disability prior to SSICH (mRS >2)
- Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 180 days (e.g. bilateral fixed dilated pupils)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control Intervention Best medical treatment (BMT) Best medical treatment i.e. active blood pressure control, seizure prophylaxis and care as according to the current guidelines. Study Intervention Best medical treatment (BMT) Early minimally invasive image guided endoscopic hematoma evacuation as an add-on therapy to BMT performed within 24 hours after SSICH symptom onset. Study Intervention Early minimally invasive image guided endoscopic hematoma evacuation Early minimally invasive image guided endoscopic hematoma evacuation as an add-on therapy to BMT performed within 24 hours after SSICH symptom onset.
- Primary Outcome Measures
Name Time Method Good functional outcome, measured by the modified Rankin Scale (mRS) At 6 months after treatment Good functional outcome is defined as a mRS of ≤3 points and will be assessed as binary outcome (yes/no, final value). In this context, a mRS score of 3 points reflects the ability to walk unassisted and care for one's own bodily needs despite being moderately dependent on assistance, while a mRS score of 4 points describes a patient who is not able to walk anymore and needs assistance with all daily activities and thus marks a severe loss of patient autonomy.
- Secondary Outcome Measures
Name Time Method Mortality rate At 6 and 12 months after intervention Mortality rate as measured by death of a participant (binary outcome (yes/no)
Change of focal neurological deficit measured by the National Institute of Health Stroke Scale (NIHSS) From baseline to 6 months after intervention The NIHSS is composed of 11 items. The score for each ability is a number between 0 and 4, 0 being normal functioning and 4 being completely impaired.
Time to intervention At baseline Time to intervention, defined as the period from symptom onset/last seen well to start of surgery (start surgical measures, i.e. positioning of patient) or start of medical treatment (admission of first treatment of BMT) (continuous variable, time to event).
Total time spent in intubation measured in minutes At 7 days/discharge after intervention The total time spent in intubation measured in minutes from the start of intubation to extubation as specified in the anesthesiology report
Proportion of hematoma volume reduction rate (in the intervention group only) Directly after intervention The hematoma volume will be measured on serial cranial computer tomography (cCT) and the difference between the volume of the cCT used for surgery and the cCT directly after surgery will be calculated.
Change in Patient cognitive outcome as assessed by the Montreal-Cognitive-Assessment-Test (MOCA® ) At 3 and 6 months after intervention The MOCA assesses: Short term memory. Visuospatial abilities. Executive functions. Attention, concentration and working memory. Language.18-25 = mild cognitive impairment, 10-17= moderate cognitive impairment and less than 10= severe cognitive impairment. MoCA scores range between 0 and 30. A score of 26 or over is considered to be normal.
Change in Quality of Life, assessed by Patient-Reported Outcomes Measurement Information System (PROMIS®) questionnaire At 3 and 6 months after intervention The PROMIS® questionnaire scores can be categorized as: within normal limits, mild, moderate and severe.
Morbidity rate At 6 and 12 months after intervention The morbidity rate, meaning occurrence of: Ischemic stroke, Recurrent SSICH (defined as any radiologically confirmed increase in hematoma volume postoperative/follow-up that is either asymptomatic or associated with a worsening of the focal-neurological deficit by ≥4 points on the NIHSS and/or a decrease in consciousness by ≥2 points on the GCS), Epileptic seizure, Surgical site infection (intervention group only), Any need for open neurosurgical procedures, Infections (i.e. pneumonia, urinary tract infection), Any other not defined complication that prolongs the hospital stay and/or leads to further treatment not envisaged in the original treatment plan.
Change in Patient Satisfaction Questionnaire At 3 and 6 months after intervention Patient Satisfaction as assessed by a 5- item survey on a scale of 1-5 (Score (1=worst, 5=best)
Total time spent on the intensive care unit (ICU)/stroke unit At 7 days/discharge after intervention The total time spent on the intensive care unit (ICU)/stroke unit as a continuous variable from the first admission to the ICU/stroke unit to discharge from ICU/stroke unit
Trial Locations
- Locations (10)
Centre Hopitalier Universitaire du Valais Romand
🇨🇭Sion, Switzerland
University Hospital Bern
🇨🇭Bern, Switzerland
Department of Neurosurgery, University Hospital Basel
🇨🇭Basel, Switzerland
Hopitaux Universitare Geneve
🇨🇭Geneva, Switzerland
Kantonsspital St. Gallen
🇨🇭Saint Gallen, Switzerland
Kantonsspital Winterthur
🇨🇭Winterthur, Switzerland
Universitätsspital Zürich
🇨🇭Zürich, Switzerland
Centre Hopitalier Universitaire Vaudoise
🇨🇭Lausanne, Switzerland
Ospedale Regionale di Lugano
🇨🇭Lugano, Switzerland
Luzerner Kantonsspital
🇨🇭Luzern, Switzerland